Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell TAK and other ETFs, options, and stocks.

About TAK

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. 

CEO
Christophe Weber
CEOChristophe Weber
Employees
47,455
Employees47,455
Headquarters
Osaka, Osaka
HeadquartersOsaka, Osaka
Founded
1781
Founded1781
Employees
47,455
Employees47,455

TAK Key Statistics

Market cap
57.17B
Market cap57.17B
Price-Earnings ratio
71.67
Price-Earnings ratio71.67
Dividend yield
3.36%
Dividend yield3.36%
Average volume
2.62M
Average volume2.62M
High today
$17.88
High today$17.88
Low today
$17.71
Low today$17.71
Open price
$17.76
Open price$17.76
Volume
2.16M
Volume2.16M
52 Week high
$18.82
52 Week high$18.82
52 Week low
$12.99
52 Week low$12.99

TAK News

TipRanks 1d
Takeda’s TAK-861 Narcolepsy Study Moves Forward, Extending the Long-Term Bet on Sleep Disorders

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study. The new Takeda study, officially titled “A Long-term Extension Study t...

TipRanks 1d
Takeda Advances Fazirsiran Phase 3 Liver Study, Keeping Rare-Disease Growth Story in Play

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study. Takeda (TAK) is running a late-stage study called “A Randomized, Doubl...

TipRanks 1d
Takeda Maps Narcolepsy in Spain: What This New Epidemiology Study Means for Investors

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study. The study Epidemiology of Narcolepsy Type 1 and Type 2 in Spain aims t...

Analyst ratings

53%

of 15 ratings
Buy
53.3%
Hold
40%
Sell
6.7%

More TAK News

TipRanks 5d
Takeda, Protagonist announce FDA acceptance of rusfertide new drug application

Takeda (TAK) and Protagonist Therapeutics (PTGX) announced that the FDA accepted the new drug application and granted priority review for rusfertide. Rusfertide...

TipRanks 5d
Takeda and Protagonist Win FDA Priority Review for First-in-Class Polycythemia Vera Drug

The latest announcement is out from Takeda Pharmaceutical Co ( (JP:4502) ). Takeda and Protagonist Therapeutics said the U.S. Food and Drug Administration has...

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.